About this FactMed analysis covering adverse side effect reports of ALBUMINAR-25 patients who developed PYREXIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 3 individuals taking ALBUMINAR-25 reported PYREXIA to the FDA. A total of 49 ALBUMINAR-25 drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALBUMINAR-25 and PYREXIA. In doing so, we compare ALBUMINAR-25 with other drugs that cause PYREXIA, to help you evaluate whether or not ALBUMINAR-25 causes PYREXIA. Likewise, this page shows the most highly-reported side effects of ALBUMINAR-25, so you can see if PYREXIA ranks among ALBUMINAR-25's most well-known side effects.
Summary Statistics
Reports of ALBUMINAR-25 causing PYREXIA: 3
Reports of any side effect of ALBUMINAR-25 : 49
Percentage of ALBUMINAR-25 patients where PYREXIA is a reported side effect: 6.1224%

FDA reports of any drug causing PYREXIA : 111364
Average percentage for all medicated patients where PYREXIA is reported as a complication: 0.6980%

Physician opinion on ALBUMINAR-25 as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALBUMINAR-25:
PRODUCT USED FOR UNKNOWN INDICATION ( 9 patients )
HYPOALBUMINAEMIA ( 6 patients )
CARDIAC FAILURE ( 2 patients )
SURGERY ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
HAEMODYNAMIC INSTABILITY ( 2 patients )
METASTASES TO LYMPH NODES ( 2 patients )
NEPHROTIC SYNDROME ( 2 patients )
RENAL FAILURE ACUTE ( 2 patients )
URINE OUTPUT DECREASED ( 2 patients )
HEPATIC CIRRHOSIS ( 2 patients )
HYPOTENSION ( 2 patients )
MYASTHENIA GRAVIS ( 1 patients )
PLASMAPHERESIS ( 1 patients )
LIVER DISORDER ( 1 patients )
PNEUMONIA ( 1 patients )
ASCITES ( 1 patients )
CENTRAL VENOUS PRESSURE DECREASED ( 1 patients )
GENERALISED OEDEMA ( 1 patients )
LYMPHANGIOMA ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with PYREXIA:

HUMIRA (7595 patients)
ASPIRIN (5953 patients)
REMICADE (5234 patients)
METHOTREXATE (5232 patients)
PREDNISONE (4893 patients)
PREDNISOLONE (4557 patients)
HEPARIN SODIUM INJECTION (4324 patients)
ENBREL (3597 patients)
ACETAMINOPHEN (3597 patients)
ZOMETA (3558 patients)
AVONEX (3381 patients)
LASIX (3343 patients)
OMEPRAZOLE (3235 patients)
FOSAMAX (3183 patients)
FOLIC ACID (3123 patients)
CYCLOPHOSPHAMIDE (2893 patients)
DEXAMETHASONE (2712 patients)
NEXIUM (2584 patients)
LIPITOR (2506 patients)
ALLOPURINOL (2390 patients)
VIOXX (2386 patients)
FUROSEMIDE (2225 patients)
TYSABRI (2085 patients)
CYCLOSPORINE (2084 patients)
PREDNISONE TAB (2069 patients)
LAMICTAL (2036 patients)
REVLIMID (2011 patients)
SYNTHROID (2005 patients)
EXJADE (1957 patients)
LISINOPRIL (1926 patients)
NEURONTIN (1875 patients)
COUMADIN (1867 patients)
DECADRON (1858 patients)
FLUOROURACIL (1855 patients)
SOLIRIS (1852 patients)
NEORAL (1851 patients)
IBUPROFEN (1821 patients)
OXYCONTIN (1817 patients)
PROTONIX (1801 patients)
NORVASC (1795 patients)
NEXAVAR (1792 patients)
AREDIA (1777 patients)
ZOFRAN (1744 patients)
LEVOTHYROXINE SODIUM (1724 patients)
CISPLATIN (1721 patients)
SIMVASTATIN (1710 patients)
CLOZARIL (1707 patients)
ATENOLOL (1688 patients)
SEROQUEL (1685 patients)
PRILOSEC (1664 patients)
XANAX (1646 patients)
POTASSIUM CHLORIDE (1630 patients)
VANCOMYCIN (1628 patients)
GLEEVEC (1612 patients)
TEGRETOL (1579 patients)
ACYCLOVIR (1579 patients)
ALBUTEROL (1571 patients)
RIBAVIRIN (1549 patients)
BACTRIM (1547 patients)
ZOLOFT (1539 patients)
AMBIEN (1527 patients)
ATIVAN (1510 patients)
CARBOPLATIN (1500 patients)
LORAZEPAM (1490 patients)
LANSOPRAZOLE (1456 patients)
PEGASYS (1452 patients)
PAXIL (1441 patients)
FLUCONAZOLE (1434 patients)
VITAMIN D (1421 patients)
PLAVIX (1418 patients)
VELCADE (1406 patients)
GABAPENTIN (1399 patients)
HYDROCHLOROTHIAZIDE (1378 patients)
MYCOPHENOLATE MOFETIL (1360 patients)
LYRICA (1337 patients)
LEVAQUIN (1331 patients)
CIPROFLOXACIN (1317 patients)
MORPHINE (1301 patients)
FAMOTIDINE (1292 patients)
DIOVAN (1290 patients)
CYTARABINE (1286 patients)
VICODIN (1276 patients)
CLONAZEPAM (1268 patients)
DIGOXIN (1263 patients)
REBIF (1245 patients)
CELEBREX (1242 patients)
OXYCODONE HCL (1232 patients)
FORTEO (1223 patients)
VINCRISTINE (1218 patients)
CALCIUM (1213 patients)
DOXORUBICIN HCL (1177 patients)
ZOCOR (1167 patients)
TAXOTERE (1156 patients)
NEUPOGEN (1156 patients)
WARFARIN SODIUM (1148 patients)
AMLODIPINE (1146 patients)
METFORMIN HCL (1138 patients)
PREVACID (1132 patients)
AMOXICILLIN (1126 patients)
BETASERON (1118 patients)
CLOZAPINE (1106 patients)
PERCOCET (1100 patients)
ETOPOSIDE (1099 patients)
TOPROL-XL (1093 patients)
IMMUCYST (1091 patients)
VOLTAREN (1078 patients)
MULTI-VITAMINS (1072 patients)
METHYLPREDNISOLONE (1069 patients)
ZANTAC (1065 patients)
AUGMENTIN '125' (1051 patients)
LEXAPRO (1047 patients)
BENADRYL (1040 patients)
RITUXIMAB (1037 patients)
TACROLIMUS (1037 patients)
CYMBALTA (1037 patients)
TYLENOL (CAPLET) (1033 patients)
DIAZEPAM (1027 patients)
SINGULAIR (1018 patients)
ACCUTANE (1010 patients)
LANTUS (1006 patients)
SOLU-MEDROL (1005 patients)
AVASTIN (1000 patients)
FENTANYL (1000 patients)
CRESTOR (986 patients)
TRAMADOL HCL (977 patients)
SYNAGIS (969 patients)
METOPROLOL TARTRATE (953 patients)
LEVOFLOXACIN (948 patients)
ZYPREXA (943 patients)
TAXOL (932 patients)
INSULIN (922 patients)
BEVACIZUMAB (921 patients)
AZATHIOPRINE (915 patients)
PACLITAXEL (915 patients)
PEG-INTRON (912 patients)
DIFLUCAN (912 patients)
TYLENOL (910 patients)
LOVENOX (906 patients)
XELODA (900 patients)
HEPARIN (899 patients)
CLARITHROMYCIN (897 patients)
AFINITOR (893 patients)
ARANESP (890 patients)
THYMOGLOBULIN (888 patients)
DURAGESIC-100 (887 patients)
RECLAST (886 patients)
NEULASTA (885 patients)
EFFEXOR (883 patients)
MAGNESIUM OXIDE (879 patients)
PREDONINE (878 patients)
OXALIPLATIN (878 patients)
COMPAZINE (870 patients)
FLAGYL (867 patients)
ALPRAZOLAM (860 patients)
LOXONIN (852 patients)
ZYRTEC (852 patients)
MULTI-VITAMIN (842 patients)
RISPERDAL (840 patients)
ADVAIR DISKUS 100/50 (840 patients)
DEPAKENE (836 patients)
DOCETAXEL (836 patients)
VALTREX (820 patients)
CALCIUM CARBONATE (817 patients)
PROGRAF (812 patients)
PANTOPRAZOLE (810 patients)
CELLCEPT (798 patients)
ZITHROMAX (798 patients)
THALIDOMIDE (791 patients)
KLONOPIN (788 patients)
BACLOFEN (782 patients)
KETEK (782 patients)
LAMIVUDINE (775 patients)
GEMZAR (775 patients)
DIANEAL (770 patients)
PROZAC (765 patients)
ROCEPHIN (760 patients)
COPEGUS (759 patients)
KALETRA (756 patients)
LORTAB (753 patients)
SPIRIVA (751 patients)
WELLBUTRIN (750 patients)
CELEXA (748 patients)
COLACE (748 patients)
RANITIDINE (748 patients)
MORPHINE SULFATE (745 patients)
MUCOSTA (742 patients)
ALDACTONE (742 patients)
CAPECITABINE (739 patients)
CERTICAN (735 patients)
BYETTA (730 patients)
REBETOL (726 patients)
VITAMIN B-12 (726 patients)
DILAUDID (724 patients)
ENALAPRIL MALEATE (716 patients)
SPIRONOLACTONE (715 patients)
AMITRIPTYLINE HCL (707 patients)
PARACETAMOL (706 patients)
RAMIPRIL (691 patients)
REGLAN (690 patients)
NYSTATIN (688 patients)
ONDANSETRON (682 patients)
PREMARIN (681 patients)
METRONIDAZOLE (670 patients)
TASIGNA (670 patients)
LEUCOVORIN CALCIUM (670 patients)
AVELOX (669 patients)
PEPCID (665 patients)
CARBAMAZEPINE (664 patients)
NITROGLYCERIN (664 patients)
ALLEGRA (661 patients)
Most common side effects for patients taking ALBUMINAR-25:
BLOOD PRESSURE DECREASED (11 patients)
INFUSION RELATED REACTION (7 patients)
HEPATITIS C POSITIVE (4 patients)
OXYGEN SATURATION DECREASED (4 patients)
HEPATIC FAILURE (3 patients)
HEPATITIS C ANTIBODY POSITIVE (3 patients)
TACHYCARDIA (3 patients)
HEPATITIS C VIRUS TEST POSITIVE (3 patients)
ANTINUCLEAR ANTIBODY POSITIVE (3 patients)
PYREXIA (3 patients)
HYPERSENSITIVITY (3 patients)
CHILLS (3 patients)
BLOOD CULTURE POSITIVE (2 patients)
PLATELET COUNT DECREASED (2 patients)
LOSS OF CONSCIOUSNESS (2 patients)
PRODUCT QUALITY ISSUE (2 patients)
KLEBSIELLA INFECTION (2 patients)
BACTERIAL INFECTION (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
HYPOXIA (2 patients)
HYPOTENSION (2 patients)
PRURITUS (2 patients)
PULMONARY EMBOLISM (2 patients)
RASH (2 patients)
HEPATITIS C RNA POSITIVE (2 patients)
CROHN'S DISEASE (2 patients)
RESTLESSNESS (2 patients)
TRANSMISSION OF AN INFECTIOUS AGENT VIA A MEDICINAL PRODUCT (2 patients)
HEPATITIS B VIRUS TEST POSITIVE (2 patients)
HEPATITIS B POSITIVE (2 patients)
DYSKINESIA (2 patients)
HEPATITIS (2 patients)
HEPATITIS C (2 patients)
HEADACHE (2 patients)
FOAMING AT MOUTH (2 patients)
FLUSHING (2 patients)
FATIGUE (1 patients)
HAEMOGLOBIN DECREASED (1 patients)
HAEMOLYSIS (1 patients)
EYE SWELLING (1 patients)
ENTEROCOLONIC FISTULA (1 patients)
HEPATIC FUNCTION ABNORMAL (1 patients)
DYSPNOEA (1 patients)
HEPATITIS B CORE ANTIGEN POSITIVE (1 patients)
DRUG HYPERSENSITIVITY (1 patients)
HEPATITIS B SURFACE ANTIGEN POSITIVE (1 patients)
DIARRHOEA (1 patients)
ABDOMINAL DISCOMFORT (1 patients)
CYANOSIS (1 patients)
CULTURE URINE POSITIVE (1 patients)
CORONARY ARTERY INSUFFICIENCY (1 patients)
COOMBS DIRECT TEST POSITIVE (1 patients)
COMPLICATIONS OF TRANSPLANTED LIVER (1 patients)
CATHETER SITE HAEMORRHAGE (1 patients)
CARDIO-RESPIRATORY ARREST (1 patients)
BLOOD PRESSURE SYSTOLIC DECREASED (1 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (1 patients)
BLOOD PRESSURE FLUCTUATION (1 patients)
LABORATORY TEST ABNORMAL (1 patients)
LARGE INTESTINE PERFORATION (1 patients)
LIP SWELLING (1 patients)
LIVER TRANSPLANT (1 patients)
BLOOD GLUCOSE INCREASED (1 patients)
NEUTROPHIL COUNT DECREASED (1 patients)
NOSOCOMIAL INFECTION (1 patients)
ORTHOPNOEA (1 patients)
BLOOD FIBRINOGEN DECREASED (1 patients)
PALLOR (1 patients)
BLOOD CREATININE INCREASED (1 patients)
PNEUMONIA KLEBSIELLA (1 patients)
POST PROCEDURAL COMPLICATION (1 patients)
PRODUCT OUTER PACKAGING ISSUE (1 patients)
PRODUCT PACKAGING QUANTITY ISSUE (1 patients)
BLOOD BILIRUBIN INCREASED (1 patients)
PROTHROMBIN TIME PROLONGED (1 patients)
BACK PAIN (1 patients)
ASTHENIA (1 patients)
PULMONARY OEDEMA (1 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (1 patients)
ANAPHYLACTIC SHOCK (1 patients)
RECTAL HAEMORRHAGE (1 patients)
RENAL DISORDER (1 patients)
ANAPHYLACTIC REACTION (1 patients)
RETROPERITONEAL ABSCESS (1 patients)
SEROLOGY POSITIVE (1 patients)
SWELLING FACE (1 patients)
ALANINE AMINOTRANSFERASE INCREASED (1 patients)
ADVERSE EVENT (1 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (1 patients)
URINARY TRACT INFECTION FUNGAL (1 patients)
URINE OUTPUT DECREASED (1 patients)
URTICARIA (1 patients)
VENA CAVA THROMBOSIS (1 patients)
WHITE BLOOD CELL COUNT DECREASED (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALBUMINAR-25


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PYREXIA and ALBUMINAR-25, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALBUMINAR-25, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALBUMINAR-25. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALBUMINAR-25 experts. If you are a healthcare provider experienced in prescribing ALBUMINAR-25, please register here.
giCould not connect: